Artificial intelligence (AI) is fundamentally reshaping how new drugs are discovered, designed, and brought to market. In 2026, AI in drug discovery is no longer an experimental add‑on used by a handful of biotech startups—it has become a core strategic capability for pharmaceutical companies, contract research organizations (CROs), and academic research labs worldwide.